Labgenomics announced on the 27th that it attended the '75th Autumn Academic Conference of the Korean Society of Pathologists' held at The-K Hotel in Seoul from the 25th to the 27th. They set up a promotional booth and introduced three types of non-genetic solid tumor gene panel tests called 'OTD (Omni Tumor Detect)' to pathology specialists and others.
Labgenomics' non-genetic solid tumor gene panel tests, the three OTD types, are NGS (Next-Generation Sequencing) testing services for cancer patients. They are categorized into Solid, Liquid, and Lung. Since August, Labgenomics has been providing the 'NGS Companion Diagnostic Test for Cancer (ODxTT)' service, used for targeted anticancer drug treatment of non-small cell lung cancer patients, at the Cancer Diagnosis Center of Konyang University Hospital, the first in the diagnostic industry.
The OTD tests provided by Labgenomics include 14 essential solid tumor genes designated by the Ministry of Health and Welfare. Since they are eligible for selective reimbursement, it is expected to improve accessibility for cancer patients. The OTD-Liquid test, which analyzes ctDNA (Circulating Tumor DNA) in the patient's blood to detect tumor gene mutations, offers a useful testing service for patients who have difficulty undergoing tissue biopsy.
OTD-Lung is the first in Korea to utilize the NGS companion diagnostic panel ODxTT (Oncomine Diagnosis Target Test), which has received IVD (In Vitro Diagnostic Medical Device) approval from the Ministry of Food and Drug Safety. It enables analysis of genes related to non-small cell lung cancer (NSCLC), including four companion diagnostic genes. It is emerging as an essential diagnostic method for drug safety and personalized treatment.
A Labgenomics official stated, "The three NGS-based cancer panel tests OTD introduced this time are personalized tests considering the patient's genetic profile and risk. Selecting the optimal testing method will help not only in prognosis confirmation but also in establishing patient-tailored treatment strategies."
They added, "We are currently discussing with various tertiary hospitals to expand the introduction of the three OTD cancer panel tests that can assist in personalized treatment for patients."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
